Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets globally. Its portfolio includes a wide range of products for various therapeutic areas. For infectious disease, it offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI. In oncology, it has EVOMELA and KYPROLIS for multiple myeloma, RYLAZE for acute lymphoblastic leukemia, and QARZIBA for neuroblastoma. It also provides FILSPARI for immunoglobulin a nephropathy, TZIELD to delay type 1 diabetes onset, and VAXNEUVANCE for pneumococcal disease. Additionally, it develops pipeline candidates such as ACLX-002, Ciforadenant, and Lasofoxifene for oncology, Ensifentrine for respiratory disease, and VK2809 for hepatology.

Ligand Pharmaceuticals is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol LGND. The company is based in the United States and trades in US Dollars (USD). As a Nasdaq-listed stock, it is subject to the exchange's listing requirements and is accessible to investors through major brokerage platforms. The currency denomination in USD makes it straightforward for US-based investors, while international investors may need to consider currency exchange rates when trading.

Ligand Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies focus on using living organisms or their derivatives to develop drugs and therapies. Ligand's work involves discovering, developing, and licensing biopharmaceutical assets, which places it firmly in this innovative field. The company's products span multiple therapeutic areas including infectious disease, oncology, neurology, and rare diseases, reflecting the broad scope of biotechnology research and development.

Ligand Pharmaceuticals has a diverse portfolio of approved products and pipeline candidates. Key approved products include EVOMELA and KYPROLIS for multiple myeloma, FILSPARI for immunoglobulin a nephropathy, TZIELD for delaying type 1 diabetes, and VAXNEUVANCE for pneumococcal disease. It also offers RYLAZE for acute lymphoblastic leukemia, QARZIBA for neuroblastoma, and NOXAFIL for fungal infections. In neurology, it has FYCOMPA and SESQUIENT, while MEKINIST is used in cardiology. Additionally, VEKLURY is an antiviral for COVID-19. The pipeline includes candidates like ACLX-002 and Ciforadenant for oncology, Ensifentrine for respiratory disease, and VK2809 for hepatology.

Ligand Pharmaceuticals operates as a biopharmaceutical company that develops and licenses biopharmaceutical assets globally. Its business model focuses on discovering and developing drug candidates, then partnering with other pharmaceutical companies to commercialize them. This licensing approach allows Ligand to generate revenue through upfront payments, milestone payments, and royalties on product sales. By leveraging its expertise in drug development and its portfolio of assets, the company reduces the risk and cost of bringing drugs to market while benefiting from the sales success of its partners. The company's extensive product portfolio spans multiple therapeutic areas, providing diversified revenue streams.